skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Experience with alendronate treatment for four years among Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures

Original Research

(1360) Views  (403) Full article downloads

Authors: Jun Iwamoto, Yoshihiro Sato, Mitsuyoshi Uzawa, et al

Published Date December 2010 Volume 2010:6 Pages 593 - 600
DOI: http://dx.doi.org/10.2147/TCRM.S15812

Jun Iwamoto1 Yoshihiro Sato2 Mitsuyoshi Uzawa3 Tsuyoshi Takeda1 Hideo Matsumoto1
1Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo; 2Department of Neurology, Mitate Hospital, Fukuoka; 3Department of Orthopaedic Surgery, Keiyu Orthopaedic Hospital, Gunma, Japan

Purpose: A retrospective study based on a conventional medical practice was performed to evaluate the outcome of alendronate treatment for four years in Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.
Methods: Twenty-nine Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures (mean age at baseline 61.0 years) who had been treated with alendronate for over four years in our outpatient clinic were studied. Lumbar spine or total hip bone mineral density (BMD) was measured using dual energy x-ray absorptiometry, and urinary levels of cross-linked N-terminal telopeptides of type I collagen (NTX) and serum levels of bone-specific alkaline phosphatase were monitored during the four-year treatment period.
Results: Urinary NTX and serum bone-specific alkaline phosphatase levels decreased (-44.4% at three months and -61.2% at four years, respectively) and lumbar spine and total hip BMD increased (+13.9% and +9.2% at four years, respectively), compared with baseline values. No serious adverse events were observed, including osteonecrosis of the jaw, femoral diaphysis atypical fractures, or atrial fibrillation.
Conclusion: To our knowledge, this is the first report of the outcome of alendronate treatment for four years in Japanese men with an increased risk for fractures. Alendronate suppressed bone turnover and increased lumbar spine and total hip BMD from baseline over the course of the four-year treatment period without causing any severe adverse events in Japanese men with osteoporosis or osteopenia and clinical risk factors for fractures.

Keywords: alendronate, bone mineral density, fracture risk, men, osteoporosis, osteopenia




 

Other articles by Dr Jun Iwamoto



Readers of this article also read:

Review of the safety and efficacy of risedronate for the treatment of male osteoporosis
Management of glucocorticoids-induced osteoporosis: role of teriparatide
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Seven years’ experience with alendronate in postmenopausal Japanese women with osteoporosis
Role of teriparatide in treatment of glucocorticoid-induced osteoporosis
Comparative evaluation of prophylactic single-dose intravenous antibiotic with postoperative antibiotics in elective urologic surgery
Does smoking really protect from recurrent aphthous stomatitis?
A systematic review of nonrandomized controlled trials on the curative effects of aquatic exercise
Efficacy and safety of bazedoxifene for postmenopausal osteoporosis
Effect of educational intervention using the Internet on quantitative ultrasound parameters in prevention of osteoporosis: a randomized controlled trial in young Japanese women